MET and glioblastoma: In vivo endothelial cell-specific knockout of MET (through the generation of Tie-Cre Metfl/fl mice) led to normalised vasculature, reduced intra-tumoural hypoxia, slowed glioblastoma growth and importantly, sensitised glioblastoma tumours to temozolomide treatment, prolonging mouse survival [40].